Evaluation on the Clinical Application Effect of Recombinant Avian Influenza Virus(H5+H7)Trivalent Inactivated Vaccines in Chickens
In order to evaluate the clinical application effect of recombinant avian influenza virus(H5+H7)trivalent inactivated vaccines(H5N1 Re-11+Re-12 strain and H7N9 H7 Re-2 strain)in chickens and the rationality of current vaccination program,940 farms with more than 500 chickens were investigated in Henan Province,in which,328 farms were selected for detection of immune antibody. It was found that,within one week after vaccination,some adverse reactions revealed in 190 farms,accounting for 20.21%(190/940);avian influenza outbreaks in 140 farms were detected,accounting for 14.89%(140/940);and dead cases were found in 51 farms,accounting for 5.43%(51/940). The proportions of chickens with adverse reactions,being infected and dead were 0.11%,0.09% and 0.04%,respectively. It was found that,by hemagglutination(HA)and hemagglutination inhibition(HI)test for serum samples,the farm/flock qualified rates of H5 Re-11,H5 Re-12 and H7 Re-2 strain were 97.56%,96.34% and 98.17%,respectively,and their positive rates of immune antibodies were 94.20%,92.70% and 94.67%,respectively. It was concluded that the recombinant avian influenza virus(H5+H7)trivalent inactivated vaccine could receive good effect in chickens,with lower level of adverse reaction. However,any adverse factors therefrom should be eliminated to the greatest extent during the process of vaccination,which should be monitored regularly,and the vaccination program should also be timely adjusted. Some references were provided for the application of vaccines against highly pathogenic avian influenza virus in China.